AbbVie (ABBV) Revenue & Revenue Breakdown

AbbVie's yearly revenue for 2025 was $61.16B, representing an increase of 8.57% compared to 2024. The company's yearly revenue for 2024 was $56.33B, representing an increase of 3.71% compared to 2023. ABBV's yearly revenue for 2023 was $54.32B, representing a decrease of -6.44% compared to 2022.

AbbVie's quarterly revenue for Q1 2026 was $15B, a -9.72% decrease from the previous quarter (Q4 2025), and a 12.43% increase year-over-year (Q1 2025). The company's quarterly revenue for Q4 2025 was $16.62B, a 5.34% increase from the previous quarter (Q3 2025), and a 10.04% increase year-over-year (Q4 2024). ABBV's quarterly revenue for Q3 2025 was $15.78B, a 2.29% increase from the previous quarter (Q2 2025), and a 9.10% increase year-over-year (Q3 2024).

AbbVie's revenue growth rate for the last 3 years (2023-2025) was 12.60%, and for the last 5 years (2021-2025) was 8.83%.

AbbVie's revenue streams in c 25 are VENCLEXTA, Other Products, MAVYRET, Linzess/Constella, Imbruvica, Vraylar, Ubrelvy, Qulipta, Other Neuroscience, Duodopa, Botox Therapeutic, SKYRIZI, RINVOQ, H U M I R A, Ozurdex, Other Eye Care, Lumigan/Ganfort, Alphagan/Combigan, Other Aesthetics, Juvederm Collection, and Botox Cosmetic. VENCLEXTA generated $2.79B in revenue, accounting 4.80% of the company's total revenue, up 8.09% year-over-year. Other Products generated $2.63B in revenue, accounting 4.52% of the company's total revenue, down -13.36% year-over-year. MAVYRET generated $1.32B in revenue, accounting 2.26% of the company's total revenue, up 0.46% year-over-year. Linzess/Constella generated $907M in revenue, accounting 1.56% of the company's total revenue, down -4.93% year-over-year. Imbruvica generated $2.87B in revenue, accounting 4.93% of the company's total revenue, down -14.28% year-over-year. Vraylar generated $3.62B in revenue, accounting 6.22% of the company's total revenue, up 10.84% year-over-year. Ubrelvy generated $1.27B in revenue, accounting 2.18% of the company's total revenue, up 26.34% year-over-year. Qulipta generated $1.04B in revenue, accounting 1.78% of the company's total revenue, up 57.45% year-over-year. Other Neuroscience generated $207M in revenue, accounting 0.36% of the company's total revenue, down -38.76% year-over-year. Duodopa generated $381M in revenue, accounting 0.65% of the company's total revenue, down -14.77% year-over-year. Botox Therapeutic generated $3.77B in revenue, accounting 6.48% of the company's total revenue, up 14.80% year-over-year. SKYRIZI generated $17.56B in revenue, accounting 30.19% of the company's total revenue, up 49.87% year-over-year. RINVOQ generated $8.3B in revenue, accounting 14.27% of the company's total revenue, up 39.07% year-over-year. H U M I R A generated $4.54B in revenue, accounting 7.80% of the company's total revenue, down -49.52% year-over-year. Ozurdex generated $493M in revenue, accounting 0.85% of the company's total revenue, down -0.20% year-over-year. Other Eye Care generated $1.01B in revenue, accounting 1.73% of the company's total revenue, up 19.13% year-over-year. Lumigan/Ganfort generated $410M in revenue, accounting 0.70% of the company's total revenue, down -4.43% year-over-year. Alphagan/Combigan generated $197M in revenue, accounting 0.34% of the company's total revenue, down -20.56% year-over-year. Other Aesthetics generated $1.26B in revenue, accounting 2.17% of the company's total revenue, down -1.09% year-over-year. Juvederm Collection generated $993M in revenue, accounting 1.71% of the company's total revenue, down -15.63% year-over-year. Botox Cosmetic generated $2.6B in revenue, accounting 4.47% of the company's total revenue, down -4.34% year-over-year.

For the fiscal year ending Dec 25, the largest source of revenue of AbbVie was SKYRIZI. This segment made a revenue of $17.56B, representing 30.19% of the company's total revenue.